Stephen F. Hobbiger
GlaxoSmithKline (United Kingdom)(GB)
Publications by Year
Research Areas
Acute Ischemic Stroke Management, Traumatic Brain Injury and Neurovascular Disturbances, Health Systems, Economic Evaluations, Quality of Life, Epilepsy research and treatment, Meta-analysis and systematic reviews
Most-Cited Works
- → Balancing benefit and risk of medicines: a systematic review and classification of available methodologies(2014)118 cited
- → Safety and Tolerability of 619C89 after Acute Stroke(1998)83 cited
- → Neuroprotection as Initial Therapy in Acute Stroke(1998)59 cited
- → A Randomized, Double‐Blind, Placebo‐Controlled Ascending Dose Tolerance Study of 619C89 in Acute Stroke(1995)18 cited
- → Pharmacokinetics of 619C89, a novel neuronal sodium channel inhibitor, in acute stroke patients after loading and discrete maintenance infusions(1996)11 cited
- → The Tolerability, Pharmacokinetics and Pharmacodynamics of Increasing Intravenous Doses of 619C89, a Novel Compound for the Acute Treatment of Stroke, in Healthy Volunteers(1995)6 cited
- → Pharmacovigilance(2013)